The mainstay of conventional vaginitis treatment is pharmacological, but often this treatment isn’t the complete solution – there’s a high recurrence rate. A probiotic treatment is important to avoid the disruption in the vaginal microbiome, otherwise known as vaginal dysbiosis.
Quatreflora Biotic is a patented and proprietary strain Saccharomyces cerevisiae CNCM I-3856 of Gnosis by Lesaffre for vaginal infections caused by fungi and bacteria with high-quality science background.
Several scientific publications explain why over the last few years, interest around the use of yeast based probiotics is increased: not only they are naturally resistant to antibiotics, and, so, it’s not necessary to evaluate their antibiotic resistance profile, but, also, because they can be used in patients undergoing antibiotic therapy.
Due to these characteristics yeast probiotics provide a considerable advantage over bacterial-origin probiotics.
The new review published in 2020 highlights the potential mechanisms of Quatreflora™ that include: inhibition of pathogen growth, inhibition of pathogen adherence to epithelial cells, immunomodulatory activity, inhibition of filamentation and biofilm development, and reduction of toxin production.
“Gaziano et al. Saccharomyces cerevisiae-Based Probiotics as Novel Antimicrobial Agents to Prevent and Treat Vaginal Infections. Front. Microbiol. 2020”.The positive effect of Quatreflora™ treatment was confirmed with a controlled clinical trial in women with vaginal candidiasis. The mechanism appears to be associated with a direct effect of S. cerevisiae on pathogens, as well as, in the case vulvovaginitis, with its immunobiotic properties.
The result for Quatreflora™ was:
- decreases the risk of recurrence by 54%
- confirms its efficacy to accelerate Candida albicans clearance after 2 months
The randomized pilot clinical poster presented at PROBIOTA AMERICAS (Vancouver, June 2019) has shown the positive results of the migration of Quatreflora Biotic (the probiotic Saccharomyces cerevisiae CNCM I-3856) from the intestine to the vagina after oral administration.
https://www.jscimedcentral.com/Obstetrics/obstetrics-5-1112.pdf
